Skip to content

JBIO JBIO Other Non-Current Assets

Other Non-Current Assets at other companies

Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$8.48M-54.6%
Vera Therapeutics logo
Vera TherapeuticsVERA
$5.94M+494%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$256K0.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$297K-18.9%
Vor Biopharma logo
Vor BiopharmaVOR
$2.41M+1.6%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$888K+81.6%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's other non-current assets?
JBIO (JBIO) reported other non-current assets of $69K in Q1 2026.
What is the long-term trend for JBIO's other non-current assets?
Over 4 years (2021 to 2025), JBIO's other non-current assets has grown at a -30.9% compound annual growth rate (CAGR), from $302K to $69K.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.